ARCHIVES

NCI FY94 Budget By Mechanism Under House, Senate Mark

This article is from The Cancer Letter archive.

Vol. 19 No. 37 | September 24, 1993

Download PDF Visit The Full Archive

Related Articles

FDA Declares Taxol Orphan Drug For KS; Can IVAX Break Bristol’s Exclusivity?

August 15, 1997

NCI Begins Phase III Trial Of Shark Cartilage In NSCLC.

May 25, 2001

AICR Increasing Funds for Research, Education, Supports Successful Symposium

November 7, 1986

Also in this 12-page issue: Senate report endorses NCI’s 2015 goal.

July 22, 2005

Pharmaceutical Industry: IVAX Official Broder Objects To Orphan Drug Policies of FDA

May 9, 1997

CCRAC Approves New Grant Program For Studies Of Cancer Patient Compliance RFA to Be Issued

May 16, 1980